Department of General Thoracic Surgery China-Japan Friendship Hospital Beijing China.
Thorac Cancer. 2016 Jul;7(4):459-66. doi: 10.1111/1759-7714.12337. Epub 2016 Mar 15.
Patients with secondary malignant tracheal and main bronchial tumors may suffer severe symptoms as a result of major airway obstruction. Curative surgical resection is usually not suitable because of the presence of metastatic disease and poor performance status. In this study, the use of bronchoscopic cryosurgery to reopen the airway is analyzed.
The clinical records of 37 patients who experienced secondary maglinancies from December 2001 to January 2013 were retrospectively reviewed. Low temperature cryotherapy (-50°C to -70°C) was delivered to the central part of the tumor by cryoprobe for four to six minutes causing destruction of the tumor mass (Cryo-melt method). Subsequently, the edge of the tumor was frozen for 30 seconds to two minutes, followed by piecemeal removal of the frozen tumor tissue (Cryo-resection method).
The endpoints of the study were degree of symptomatic improvement and survival. The rates of dramatic and partial symptomatic alleviation were 57.1% and 28.6%, respectively, there were no intraoperative deaths, and median survival was 16.0 months. Prolonged survival was significantly correlated to age (under 60 years of age 22.2% vs. over 60 100%, P = 0.011), tumor location (main bronchi 0% vs. trachea 77.8%, P = 0.003), and cryorecanalization times (once 33.3% vs. twice or more 80.0%, P = 0.037).
Bronchoscopic cryorecanalization is a safe, effective, non-invasive choice for improving the symptoms of malignant airway obstruction. In addition to achieving local-regional control, the technique may also contribute to improved survival.
继发性恶性气管和主支气管肿瘤患者可能因大气道阻塞而出现严重症状。由于存在转移性疾病和较差的表现状态,通常不适合进行根治性手术切除。在这项研究中,分析了使用支气管镜冷冻手术来重新开放气道。
回顾性分析了 2001 年 12 月至 2013 年 1 月期间 37 例继发性恶性肿瘤患者的临床记录。通过冷冻探针将低温冷冻疗法(-50°C 至-70°C)输送到肿瘤中心部位,持续四到六分钟,从而破坏肿瘤组织(Cryo-melt 方法)。随后,对肿瘤边缘进行 30 秒至两分钟的冷冻,然后将冷冻的肿瘤组织进行分片切除(Cryo-resection 方法)。
本研究的终点是症状改善程度和生存情况。症状显著和部分缓解的比例分别为 57.1%和 28.6%,术中无死亡,中位生存时间为 16.0 个月。延长生存时间与年龄(<60 岁为 22.2%,≥60 岁为 100%,P=0.011)、肿瘤位置(主支气管为 0%,气管为 77.8%,P=0.003)和冷冻再通次数(一次为 33.3%,两次或以上为 80.0%,P=0.037)显著相关。
支气管镜冷冻再通术是改善恶性气道阻塞症状的一种安全、有效、非侵入性的选择。除了实现局部区域控制外,该技术还可能有助于提高生存率。